Patients with metastatic disease should undergo PD-L1 testing, and those who have PD-L1 are candidates for the combination therapy of nivolumab and ipilimumab. The presence of an oncogene and candidacy for immune checkpoint inhibitors with tumor histology and performance status and comorbidities should be factored into treatment considerations. First-line, single-agent pembrolizumab is indicated for metastatic NSCLC whose tumors express PD-L1 with no EGFR genomic aberrations.
Learn more about treatment protocols for metastatic NSCLC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan. Fast Five Quiz: Metastatic Non–Small Cell Lung Cancer - Medscape - Mar 29, 2022.